KPV, PepT1 and Colitis-Associated Tumorigenesis in Mice
This study used PepT1-overexpressing and PepT1-deficient mice to examine transporter involvement in colitis-associated tumorigenesis and KPV-related effects.
Study design
Researchers induced colitis-associated cancer with AOM/DSS, compared tumour and inflammatory measurements across mouse genotypes, examined human biopsy expression, and administered KPV to mice with or without PepT1.
What the researchers reported
PepT1 overexpression was associated with greater tumour burden and inflammation, while deletion showed the opposite pattern. KPV was associated with reduced tumorigenesis in wild-type but not PepT1-deficient mice.
What this result does not establish
The intervention evidence came from a chemically induced mouse model. Human biopsy expression was observational and does not establish that KPV prevents or treats colorectal cancer in people.
This article summarizes one published study about KPV. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards